MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on January 17, 2008; DOI: 10.1124/mol.107.042580


0026-895X/08/7304-1105-1112$20.00
Mol Pharmacol 73:1105-1112, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.042580v1
73/4/1105    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Yao, L.
Right arrow Articles by Diamond, I.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yao, L.
Right arrow Articles by Diamond, I.

Dopamine and Ethanol Cause Translocation of {epsilon}PKC Associated with {epsilon}RACK: Cross-Talk between cAMP-Dependent Protein Kinase A and Protein Kinase C Signaling Pathways

Lina Yao, Peidong Fan, Zhan Jiang, Adrienne Gordon, Daria Mochly-Rosen, and Ivan Diamond

CV Therapeutics, Inc., Palo Alto, California (L.Y., P.F., Z.J., I.D.); Ernest Gallo Clinic and Research Center, Emeryville, California (L.Y., A.G., I.D.); Departments of Neurology (L.Y., I.D.) and Cellular and Molecular Pharmacology (I.D.), and the Neuroscience Graduate Program (I.D.), University of California, San Francisco, California; and Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California (D.M.)

We found previously that neural responses to ethanol and the dopamine D2 receptor (D2) agonist 2,10,11-trihydroxy-N-propylnorapomorphine hydrobromide (NPA) involve both {epsilon} protein kinase C ({epsilon}PKC) and cAMP-dependent protein kinase A (PKA). However, little is known about the mechanism underlying ethanol- and D2-mediated activation of {epsilon}PKC and the relationship to PKA activation. In the present study, we used a new {epsilon}PKC antibody, 14E6, that selectively recognized active {epsilon}PKC when not bound to its anchoring protein {epsilon}RACK (receptor for activated C-kinase), and PKC isozyme-selective inhibitors and activators to measure PKC translocation and catalytic activity. We show here that ethanol and NPA activated {epsilon}PKC and induced translocation of both {epsilon}PKC and its anchoring protein, {epsilon}RACK to a new cytosolic site. The selective {epsilon}PKC agonist, pseudo-{epsilon}RACK, activated {epsilon}PKC but did not cause translocation of the {epsilon}PKC/{epsilon}RACK complex to the cytosol. These data suggest a step-wise activation and translocation of {epsilon}PKC after NPA or ethanol treatment, where {epsilon}PKC first translocates and binds to its RACK and subsequently the {epsilon}PKC/{epsilon}RACK complex translocates to a new subcellular site. Direct activation of PKA by adenosine-3',5'-cyclic monophosphorothioate, Sp-isomer (Sp-cAMPS), prostaglandin E1, or the adenosine A2A receptor is sufficient to cause {epsilon}PKC translocation to the cytosolic compartment in a process that is dependent on PLC activation and requires PKA activity. These data demonstrate a novel cross-talk mechanism between {epsilon}PKC and PKA signaling systems. PKA and PKC signaling have been implicated in alcohol rewarding properties in the mesolimbic dopamine system. Cross-talk between PKA and PKC may underlie some of the behaviors associated with alcoholism.


Received October 9, 2007; accepted January 17, 2008

Address correspondence to: Dr. Lina Yao, CV Therapeutics, Inc., 3172 Porter Drive, Palo Alto, CA 94304. E-mail: lina.yao{at}cvt.com







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics